PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma

References

• Armitage JO, Wiesenberger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Teng DH, Hu R, Lin H, et al MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221–5225.
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387–390.
   PubMed Web of Science ®Google Scholar
• Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008;27:5443–5453.
   PubMed Web of Science ®Google Scholar
• Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27:5477–5485.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou XY, et al PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117–127.
   PubMed Web of Science ®Google Scholar
• She QB, Solit DB, Ye Q, et al The BAD protein integrates survival signaling by EGFR / MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287–297.
   PubMed Web of Science ®Google Scholar
• Wang J, Ouyang W, Li J, et al Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Cancer Res 2005;65:6601–6611.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Mulholland DJ, Valamehr B, et al PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 2008;28:3281–3289.
   PubMed Web of Science ®Google Scholar
• Chen Z, Trotman LC, Shaffer D, et al Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725–730.
   PubMed Web of Science ®Google Scholar
• Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675–680.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Finlay CA, Hinds PW. P53 is a tumor suppressor gene. Cell 2004;116:S67–S69, 61p following S69.
   PubMedGoogle Scholar
• Young KH, Leroy K, Moller MB, et al Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088–3098.
   PubMed Web of Science ®Google Scholar
• Podsypanina K, Ellenson LH, Nemes A, et al Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563–1568.
   PubMed Web of Science ®Google Scholar
• Knobbe CB, Lapin V, Suzuki A, et al The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 2008;27:5398–5415.
   PubMed Web of Science ®Google Scholar
• RT, Tripp S, Perkins SL, et al Analysis of the PI-3-kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod Pathol 2003;16:607–612.
   PubMed Web of Science ®Google Scholar
• Fridberg M, Servin A, Anagnostakil L, et al Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-b II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lym 2007;48:2221–2232.
   PubMed Web of Science ®Google Scholar
• Abubaker J, Bavi PP, Al-Harbi S, et al PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21:2368–2370.
   PubMed Web of Science ®Google Scholar
• Robledo C, García JL, Caballero D, et al Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer 2009;115:3728–3737.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, et al Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008;27:5387–5397.
   PubMed Web of Science ®Google Scholar
• Xiao C, Srinivasan L, Calado DP, et al Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008;9:405–414.
   PubMed Web of Science ®Google Scholar
• Wiencke JK, Zheng S, Jelluma N, et al Methylation of the PTEN promoter defines low grade gliomas and secondary glioblastoma. Neuro Oncol 2007;9:271–279.
   PubMed Web of Science ®Google Scholar
• Ross AH, Gericke A. Phosphorylation keeps PTEN phosphatase closed for business. Proc Natl Acad Sci USA 2009;106:1297–1298.
   PubMed Web of Science ®Google Scholar
• Wang X, Trotman LC, Koppie T, et al NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007;128:129–139.
   PubMed Web of Science ®Google Scholar
• Sakai A, Thieblemont C, Wellmann A, et al PTEN gene alterations in lymphoid neoplasms. Blood 1998;92:3410–3415.
   PubMed Web of Science ®Google Scholar
• Nakahara Y, Nagai H, Kinoshita T, et al Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 1998;12:1277–1280.
   PubMed Web of Science ®Google Scholar
• Pallares J, Bussaglia E, Martinez-Guitarte JL, et al Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:719–727.
   PubMed Web of Science ®Google Scholar
• Perren A, Weng LP, Boag AH, et al Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253–1260.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA et al Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003;197:657–667.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving towards a molecularly targeted approach. Blood 2005;106:1164–1174.
   PubMed Web of Science ®Google Scholar
• Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32:355–357.
   PubMed Web of Science ®Google Scholar
• Li Y, Guessous F, Kwon S, et al PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res 2008;68:1723–1731.
   PubMed Web of Science ®Google Scholar
• Vikhanskaya F, Lee MK, Mazzoletti M, et al Cancer-derived p53 mutants suppress p53-target gene expression–potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007;35:2093–2104.
   PubMed Web of Science ®Google Scholar